Ann: MMJ Receives Approval to Conduct MS Phase 2 Clinical Trials, page-3

Good news for sufferers of MS.

MMJ RECEIVES APPROVAL TO CONDUCT PHASE 2 CLINICAL TRIAL FOR TREATMENT OF MULTIPLE SCLEROSIS SYMPTOMS Highlights: • 100%-owned subsidiary, PhytoTech Therapeutics, receives Clinical Site and Ministry of Health approvals to conduct Phase 2 clinical trial of PTL201 • Phase 2 clinical trial is aimed at measuring safety and efficacy of the PTL201 capsules in treating spasticity related symptoms in multiple sclerosis (MS) patients • Phase 2 clinical trial is double-blind, randomised, placebo-controlled, parallel-group study in 70 MS patients • Success of Phase 2 will be a major step towards commercial development of the PTL201 drug for treatment of MS debilitating symptoms • Phase 2 clinical trial of PTL101 to treat refractory epilepsy in paediatric patients is proceeding as planned